SafeHeal, a Paris, France-based early-stage medtech company specialized in digestive surgery and focused on the development of the Colovac device, closed a €6m Series A financing round.
The round was led by Sofinnova Partners.
The company will use the funds for the execution of its clinical and regulatory market access program.
Founded in 2015 by MD Start, a medtech accelerator founded by Sofinnova Partners in 2008 and specialized in building companies focusing on large, unaddressed clinical needs and significant market opportunities, and led by Karl Blohm, CEO, and Anne Osdoit, Partner at MD Start and co-founder, SafeHeal develops an innovative digestive anastomosis protection device, called Colovac, designed to reduce complications and obviate the need for ostomies for colectomy patients. This technology consists of a minimally invasive and fully reversible implant that remains in place until the body’s natural healing and tissue repair processes are complete, for approximately two weeks, after which it is removed.
The company has already begun a CE mark study and has tested the device on seven patients.